Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4838077 | 0.74 | PNP (0.43) | MTAPPNP | |
| SCHEMBL505684 | 0.71 | MTAP (0.59) | MTAPPNP | |
| SCHEMBL6250412 | 0.70 | MTAP (0.39) | MTAPPNP | |
| SCHEMBL506292 | 0.67 | PNP (0.38) | MTAPPNP | |
| SCHEMBL14262857 | 0.66 | MTAP (1.00) | MTAPPNP | |
| SCHEMBL18873314 | 0.66 | MTAP (0.78) | MTAPPNP | |
| SCHEMBL30583390 | 0.66 | MTAP (1.00) | MTAPPNP | |
| SCHEMBL30924343 | 0.66 | MTAP (1.00) | MTAPPNP | |
| SCHEMBL13137591 | 0.66 | MTAP (1.00) | MTAPPNP | |
| SCHEMBL16366105 | 0.66 | MTAP (1.00) | MTAPPNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092521-A1 | Methods of Treating Diseases Using Inhibitors of Nucleoside Phosphorylases and Nucleosidases | NATIONAL INSTITUTES OF HEALTH | 2011-04-21 | — | — | US | claimed |
| US-20040110772-A1 | Inhibitors of nucleoside phosphorylases and nucleosidases | NATIONAL INSTITUTES OF HEALTH | 2004-06-10 | — | — | US | claimed |
| US-20110092521-A1 | Methods of Treating Diseases Using Inhibitors of Nucleoside Phosphorylases and Nucleosidases | NATIONAL INSTITUTES OF HEALTH | 2011-04-21 | — | — | US | disclosed |
| US-7098334-B2 | 4-amino-5H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases | INDUSTRIAL RESEARCH LIMITED (NZ) | 2006-08-29 | — | — | US | disclosed |
| US-20040110772-A1 | Inhibitors of nucleoside phosphorylases and nucleosidases | NATIONAL INSTITUTES OF HEALTH | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110772-A1 | Inhibitors of nucleoside phosphorylases and nucleosidases | PNP, RNASEL, TYMP | MTAP 4/4885PNP 1/4885 |
| US-20110092521-A1 | Methods of Treating Diseases Using Inhibitors of Nucleoside Phosphorylases and Nucleosidases | MTAP, PNP, NTPCR | MTAP 1/4885PNP 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.